207 related articles for article (PubMed ID: 37147894)
1. M2 macrophage marker CHI3L2 could serve as a potential prognostic and immunological biomarker in glioma by integrated single-cell and bulk RNA-Seq analysis.
Qian W; Wang Q; Zhang C; Zhu J; Zhang Q; Luo C
J Gene Med; 2023 Sep; 25(9):e3523. PubMed ID: 37147894
[TBL] [Abstract][Full Text] [Related]
2. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
Front Oncol; 2021; 11():611038. PubMed ID: 33937022
[TBL] [Abstract][Full Text] [Related]
3. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
[TBL] [Abstract][Full Text] [Related]
4. Integrative analysis of bulk RNA-seq and scRNA-seq data indicates the prognostic and immunologic values of SERPINH1 in glioma.
Hou S; Chen Y; Jin C; Lin N
Environ Toxicol; 2024 Jun; 39(6):3654-3665. PubMed ID: 38506564
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the m6A/m1A/m5C/m7G-related regulators on the prognosis and immune microenvironment of glioma by integrated analysis of scRNA-seq and bulk RNA-seq data.
Yang L; Huang Z; Deng Y; Zhang X; Lv Z; Huang H; Sun Q; Liu H; Liang H; He B; Hu F
J Gene Med; 2024 Feb; 26(2):e3666. PubMed ID: 38391150
[TBL] [Abstract][Full Text] [Related]
6. Cancer-associated fibroblast-associated gene IGFBP2 promotes glioma progression through induction of M2 macrophage polarization.
Zhang X; Sun X; Guo C; Li J; Liang G
Am J Physiol Cell Physiol; 2024 Jan; 326(1):C252-C268. PubMed ID: 37982173
[TBL] [Abstract][Full Text] [Related]
7. EREG is the core onco-immunological biomarker of cuproptosis and mediates the cross-talk between VEGF and CD99 signaling in glioblastoma.
Zhou Y; Xiao D; Jiang X; Nie C
J Transl Med; 2023 Jan; 21(1):28. PubMed ID: 36647156
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
[TBL] [Abstract][Full Text] [Related]
9. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
10. Expression of hub genes of endothelial cells in glioblastoma-A prognostic model for GBM patients integrating single-cell RNA sequencing and bulk RNA sequencing.
Zhao S; Ji W; Shen Y; Fan Y; Huang H; Huang J; Lai G; Yuan K; Cheng C
BMC Cancer; 2022 Dec; 22(1):1274. PubMed ID: 36474171
[TBL] [Abstract][Full Text] [Related]
11. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
12. Combined bulk RNA-seq and single-cell RNA-seq identifies a necroptosis-related prognostic signature associated with inhibitory immune microenvironment in glioma.
Wan S; Moure UAE; Liu R; Liu C; Wang K; Deng L; Liang P; Cui H
Front Immunol; 2022; 13():1013094. PubMed ID: 36466844
[TBL] [Abstract][Full Text] [Related]
13. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
Li J; Zhang Y; Qu Z; Ding R; Yin X
Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
[TBL] [Abstract][Full Text] [Related]
14.
Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
[TBL] [Abstract][Full Text] [Related]
15. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
16. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
[TBL] [Abstract][Full Text] [Related]
17. PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma.
Wang J; Wu N; Feng X; Liang Y; Huang M; Li W; Hou L; Yin C
Front Immunol; 2022; 13():1052692. PubMed ID: 36685506
[TBL] [Abstract][Full Text] [Related]
18. Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas.
Song D; Yang Q; Li L; Wei Y; Zhang C; Du H; Ren G; Li H
Front Immunol; 2024; 15():1372113. PubMed ID: 38529286
[TBL] [Abstract][Full Text] [Related]
19. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.
Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z
J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614
[TBL] [Abstract][Full Text] [Related]
20. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
